[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545060":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":41,"locations":48,"responsibleParty":74,"collaborators":27,"id":76,"slug":27,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":27,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":51,"whyStopped":27,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Centre Hospitalier Departemental Vendee","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Combination of corticosteroid and hyaluronic acid injection","EXPERIMENTAL","An injection of 1 ml if corticosteroids and an injection of 2 ml of hyaluronic acid",[13,14],"Drug: Hyaluronic acid injection","Drug: Corticosteroid injection",{"label":16,"type":17,"description":18,"interventionNames":19},"Corticosteroid injection alone","PLACEBO_COMPARATOR","An injection of 1 ml of corticosteroids and an injection of 2 ml of placebo (physiological serum).",[14,20],"Drug: Placebo injection",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Hyaluronic acid injection","An injection of 2 ml of Acid hyaluronic",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Corticosteroid injection","An injection of 1 ml of corticosteroids",[9,16],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Placebo injection","An injection of 2 ml of placebo (physiological serum)",[16],[37],{"name":38,"affiliation":39,"role":40},"Céline COZIC, Dr","Centre Hospitalier Départemental Vendée","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":46,"email":47},"Laura SOULARD","CONTACT","0251080582","+33","laura.soulard@ght85.fr",[49,63],{"facility":50,"status":51,"city":52,"state":27,"zip":27,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"CHD Vendée","RECRUITING","La Roche-sur-Yon","France","FR",{"type":56,"coordinates":57},"Point",[58,59],-1.42757,46.66974,{"lat":59,"lon":58},[62],{"name":38,"role":40,"phone":27,"phoneExt":27,"email":27},{"facility":64,"status":51,"city":65,"state":27,"zip":27,"country":53,"countryCode":54,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"CHU Nantes","Nantes",{"type":56,"coordinates":67},[68,69],-1.55336,47.21725,{"lat":69,"lon":68},[72],{"name":73,"role":40,"phone":27,"phoneExt":27,"email":27},"Christelle DARRIEUTORT-LAFFITE, Dr",{"type":75,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100545060",false,"NCT06376981","Hyaluronic Acid in Shoulder Tendinopathy","Benefit of a Subacromial Injection Combining Corticosteroid and Hyaluronic Acid Versus Corticosteroid Alone in Supraspinatus Tendinopathy","ACCTE","Inclusion Criteria:\n\n* Active patient aged between 18 and 65;\n* Patient suffering from pain compatible with supraspinatus tendinopathy for at least 2 months;\n* Patient with simple tendinopathy or partial tendon rupture;\n* Patient with tendinopathy confirmed by ultrasound or MRI;\n* Patient with an active pain visual analog scale ≥ 4 for more than 6 weeks;\n* Patient with an active pain visual analog scale ≥ 4 on the day of inclusion;\n* Patient failing medical treatment (rest, analgesics, NSAIDs, physiotherapy);\n* Patient able to follow the protocol and having given oral informed consent to take part in the research;\n* Patient affiliated to the social security system or entitled person;\n\nExclusion Criteria:\n\n* Patient suffering from a transfixing tendon rupture;\n* Patients suffering from post-traumatic tendon rupture;\n* Patients suffering from calcific tendinopathy (calcification \\> 5 mm);\n* Patients with associated glenohumeral osteoarthritis;\n* Patients with associated symptomatic acromioclavicular osteoarthritis;\n* Patients with shoulder pain for reasons other than tendinopathy (capsulitis, chronic inflammatory rheumatism, fibromyalgia, amyloidosis);\n* Patients who have had a subacromial infiltration in the previous 6 months;\n* Patients with a known allergy to one of the products including their excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl alcohol);\n* Patients with a known allergy to lidocaine;\n* Patients with a local or generalised infection, or suspected infection;\n* Patients with severe coagulation disorders or taking anticoagulants;\n* Patients with severe and\u002For uncontrolled hypertension \\> 160\u002F100 mmHg;\n* Patients with unbalanced diabetes (last HbA1c \\> 8.5%);\n* Patients with a history of addiction to psychoactive substances;\n* Patient participating in another clinical research protocol with an impact on the research objectives;\n* Patient already randomised in the study;\n* Patient who is pregnant, parturient, breastfeeding or able to procreate without effective contraception\\* in the month prior to inclusion and up to 15 days after infiltration;\n* Patients under guardianship, curators or deprived of liberty;\n* Patient under a mandate for future protection activated ;\n* Patient under family guardianship ;\n* Patient under court protection ;","ALL","18 Years","65 Years",{"count":87,"type":88},132,"ESTIMATED","INTERVENTIONAL",[91],"PHASE3","Multicentric, randomised study to compare the effectiveness on activity pain at 3 months of corticosteroid injection associated with hyaluronic acid with corticosteroids injection alone in patients with tendinopathy of the supraspinatus with clinical reevaluation at one, three and six months.",[94],"Shoulder Tendinitis",[96,97,29],"Shoulder tendinitis","Hyaluronic acid","2026-06-17",{"date":100,"type":101},"2026-06-22","ACTUAL",{"date":103,"type":101},"2024-09-19",{"date":105,"type":88},"2027-03-19",{"name":5,"class":6},2]